A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
Abstract Background Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates. It is approved for twice-daily dosing with n...
Main Authors: | Nicholas Van Hise, Russell M. Petrak, Nathan C. Skorodin, Robert M. Fliegelman, Michael Anderson, Vishal Didwania, Alice Han, Kairav Shah, Vishnu Chundi, David Hines, Ingrid Roig, Apoorv Kalra |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-10-01
|
Series: | Infectious Diseases and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40121-020-00351-0 |
Similar Items
-
A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals
by: Athena L.V. Hobbs, et al.
Published: (2022-06-01) -
Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by <i>Clostridiodes difficile</i>
by: Pedro Sánchez-Pellicer, et al.
Published: (2021-08-01) -
Association between epidemiologic case definition categories and adverse clinical outcome in patients with Clostridiodes difficile infection in San Francisco County, California: a five-year retrospective cohort study
by: Bekure B. Siraw, et al.
Published: (2023-02-01) -
Risk for Clostridiodes difficile Infection among Older Adults with Cancer
by: Mini Kamboj, et al.
Published: (2019-09-01) -
In vitro susceptibility of common Enterobacterales to eravacycline in Taiwan
by: Chun-Fu Huang, et al.
Published: (2023-04-01)